Drugs / Tetanus Vaccine, Adsorbed
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07598890 Comparator | May → Dec 2026 expected | tetanus | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06049940 Comparator | Sep → Oct 2023 | tetanus | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tetanus vaccine, adsorbed | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06049940 ↗ |
| Modality | Vaccine | “Investigational tetanus vaccine, adsorbed” NCT06049940 ↗ |
| Route | Intramuscular | “Participants will receive one dose of adsorbed tetanus vaccine via intramuscular injection into the deltoid muscle of the upper arm.” NCT07598890 ↗ |